Patents Assigned to Respivert Ltd.
  • Inhibitor of p38 MAP kinase
    Patent number: 11634406
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: April 25, 2023
    Assignee: RESPIVERT LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Inhibitor of p38 MAP kinase
    Patent number: 10815217
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: October 27, 2020
    Assignee: Respivert Ltd.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Respiratory formulations and compounds for use therein
    Patent number: 10358445
    Abstract: The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: July 23, 2019
    Assignee: RESPIVERT, LTD.
    Inventors: Peter John Murray, Stuart Thomas Onions, Jonathan Gareth Williams, Kevin Joly
  • P38 MAP kinase inhibitors
    Patent number: 10144721
    Abstract: There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: December 4, 2018
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, Ito Kazuhiro, Peter Strong, William Garth Rapeport, Catherine Elisabeth Charron, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
  • Inhibitor of p38 map kinase
    Patent number: 10045980
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: August 14, 2018
    Assignee: Respivert Ltd
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors
    Patent number: 10028959
    Abstract: The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: July 24, 2018
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
    Patent number: 9993478
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: June 12, 2018
    Assignee: Respivert, Ltd.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
  • COMPOUNDS
    Publication number: 20180118754
    Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.
    Type: Application
    Filed: November 8, 2017
    Publication date: May 3, 2018
    Applicant: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • Compounds
    Patent number: 9834560
    Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: December 5, 2017
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS
    Publication number: 20170334919
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 23, 2017
    Applicant: RESPIVERT LTD.
    Inventors: Rudy Laurent Maria Broeckx, Alex Herman Copmans, Alun John Smith, David Michel Adrien Taddei, Stuart Thomas Onions
  • 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS
    Publication number: 20170312279
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: June 29, 2017
    Publication date: November 2, 2017
    Applicant: Respivert Ltd.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Lonshaw
  • Pyrazole p38 map kinase inhibitors
    Patent number: 9771354
    Abstract: There are provided inter alia compounds of formula (I) wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: September 26, 2017
    Assignee: Respivert Ltd.
    Inventors: John King-Underwood, George Hardy, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
  • 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors
    Patent number: 9724347
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: August 8, 2017
    Assignee: Respivert, Ltd.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
  • Crystalline 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-0X0-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide
    Patent number: 9642799
    Abstract: There is provided inter alia 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide in the form of a solid crystalline hydrate and in solid crystalline anhydrous form. There are also provided dry powder pharmaceutical compositions for inhalation containing such solid crystalline forms.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 9, 2017
    Assignee: Respivert, Ltd.
    Inventors: Rudy Laurent Maria Broeckx, Walter Ferdinand Maria Filliers, Patrick Hubert J Nieste, Alex Herman Copmans, Filip Marcel Vanhoutte, Carina Leys
  • Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors
    Patent number: 9637494
    Abstract: The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 2, 2017
    Assignee: Respivert, Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
  • Inhibitor of p38 MAP kinase
    Patent number: 9624196
    Abstract: A compound of formula (XV): wherein R1 represents an amino group, a protected amino group or nitro group; or a salt thereof. The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: April 18, 2017
    Assignees: RESPIVERT LTD., TOPIVERT PHARMA LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • Phosphoinositide 3-kinase inhibitors
    Patent number: 9556184
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: January 31, 2017
    Assignee: Respivert, Ltd.
    Inventors: David Michel Adrien Taddei, Stuart Thomas Onions, Alun John Smith, Alex Herman Copmans, Rudy Laurent Maria Broeckx
  • 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4 -YL) OXY) NAPTHTHALEN-1 - YL) UREAS AS P38 MAP KNASE INHIBITORS
    Publication number: 20170007604
    Abstract: There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Application
    Filed: September 8, 2016
    Publication date: January 12, 2017
    Applicant: Respivert Ltd.
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw
  • Inhibitor of p38 map kinase
    Patent number: 9447076
    Abstract: A compound has the following formula: The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: September 20, 2016
    Assignees: RESPIVERT LTD., TOPIVERT PHARMA LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • COMPOUNDS
    Publication number: 20160264583
    Abstract: The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.
    Type: Application
    Filed: March 31, 2016
    Publication date: September 15, 2016
    Applicant: Respivert Ltd.
    Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown